Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

15.02.22		Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial (Businesswire)
24.01.22		Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva (Businesswire)
21.01.22		Ipsen Nominates Karen Witts as New Independent Board Member (Businesswire)
11.06.21		ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity (Businesswire)
01.06.21		Ipsen Announces the Launch of an Employee Shareholding Plan (Businesswire)
28.05.21		Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP) (Businesswire)
11.05.21		Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results (Businesswire)
22.04.21		Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance (Businesswire)
31.03.21		European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma (Businesswire)
26.02.21		Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma (Businesswire)
22.02.21		Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) (Businesswire)
05.02.21		Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 2021 (Businesswire)
20.01.21		Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs (Businesswire)
15.01.21		TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications (Businesswire)
01.12.20		Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook (Businesswire)
30.11.20		Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC) (Businesswire)
22.10.20		Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance (Businesswire)
25.09.20		Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer (Businesswire)
18.09.20		ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months (Businesswire)
14.09.20		Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress (Businesswire)
10.09.20		Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results (Businesswire)
25.08.20		Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting (Businesswire)
02.07.20		Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer (Businesswire)
17.06.20		Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as a First-Line Combination Treatment for Metastatic Pancreatic Cancer (Businesswire)
08.06.20		Ipsen Initiates a Share Buyback Program to Cover Its Share Allocation Plan (Businesswire)
08.06.20		Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society (Businesswire)
29.05.20		Ipsen Appoints David Loew as Chief Executive Officer (Businesswire)
23.05.20		Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence (Businesswire)
19.05.20		Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy (Businesswire)
04.05.20		Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program (Businesswire)
22.04.20		Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact (Businesswire)
01.04.20		Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 (Businesswire)
26.03.20		Ipsen Provides Update on Palovarotene Clinical Programs (Businesswire)
25.03.20		Ipsen Provides COVID-19 Update (Businesswire)
11.03.20		Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly (Businesswire)
24.01.20		Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria (Businesswire)
14.01.20		Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer (Businesswire)
06.01.20		Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy (Businesswire)
18.12.19		Ipsen Announces Departure of David Meek as Chief Executive Officer (Businesswire)
06.12.19		Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies (Businesswire)
05.11.19		Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development (Businesswire)
05.11.19		Proposed reclassification of Ipsen shares held by Mayroy (Businesswire)
31.10.19		Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019 (Businesswire)
24.10.19		Ipsen Delivers Strong Double-digit Sales Growth for the Third Quarter of 2019 and Confirms Full Year 2019 Guidance (Businesswire)
16.10.19		Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) (Businesswire)
26.09.19		Ipsen Showcases Studies at the ESMO 2019 Congress Highlighting Progress in New Approaches for Difficult-to-Treat Cancers (Businesswire)
20.09.19		Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) (Businesswire)
12.06.19		Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years (Businesswire)
30.05.19		KNDL 2019-KNSQ Mortgage Trust -- Moody's assigns definitive ratings to Five CMBS classes of KNDL 2019-KNSQ Mortgage Trust (Moodys)
24.05.19		New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 04:49
Kaufwert:	EUR
	Hinzufügen Speichern